Assessing the risk of angiotensin receptor blockers on major cardiovascular events: a systematic review and meta-analysis of randomized controlled trials
<h3>Background</h3><p dir="ltr">Angiotensin receptor blockers (ARBs) are commonly used as a treatment for many cardiovascular diseases, but their safety has been called into question. The VALUE trial found an increased risk of myocardial infarction in participants receivi...
محفوظ في:
| المؤلف الرئيسي: | Yara Wanas (8744844) (author) |
|---|---|
| مؤلفون آخرون: | Rim Bashir (8744847) (author), Nazmul Islam (14153049) (author), Luis Furuya-Kanamori (477124) (author) |
| منشور في: |
2020
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
مواد مشابهة
-
Genetic polymorphisms influencing antihypertensive drug responses
حسب: Jana El Cheikh (22330738)
منشور في: (2024) -
Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction
حسب: Rasha Kaddoura (12506936)
منشور في: (2023) -
Successful Use of Intravenous B-blocker Therapy in Cardiogenic Shock Supported With Venoarterial Extracorporeal Membrane Oxygenation: A Case Series
حسب: Alaa Rahhal (14150403)
منشور في: (2022) -
Soluble ACE2 and angiotensin II levels are modulated in hypertensive COVID-19 patients treated with different antihypertension drugs
حسب: Mohamed A. Elrayess (21398687)
منشور في: (2022) -
COMMENT ON “Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction”, Current Problems in Cardiology (2023), doi: https://doi.org/10.1016/j.cpcardiol.2023.102203
حسب: Dr Rasha Kaddoura (17823434)
منشور في: (2024)